Key result
Pericardial procainamide prolonged right atrial effective refractory period by 22%, achieving similar atrial electrophysiologic effects as a /kg intravenous dose.
Why the study?
Does intrapericardial procainamide delivery improve atrial electrophysiologic effects compared to intravenous delivery in a swine model?
RCT (n=13)
randomized
Does intrapericardial procainamide delivery improve atrial electrophysiologic effects compared to intravenous delivery in a swine model?
Intrapericardial procainamide achieves similar atrial electrophysiologic effects as high-dose intravenous delivery but at much lower doses and with minimal systemic exposure or ventricular effects in a swine model.
Answers are grounded in this paper and cite their sources.
Pericardial procainamide may enable atrial-selective effects at lower doses; leaves open translation to human AF therapy.
INTRODUCTION: Procainamide delivery into the pericardial space may produce a greater and more prolonged electrophysiologic effect, particularly in thin superficial atrial tissue, compared with intravenous delivery. METHODS AND RESULTS: Swine were randomized to sequential procainamide doses delivered intravenously (n = 6) or into the pericardial space (n = 7). The cumulative pericardial doses were 0.5, 1.5, and 3.5 mg/kg, and the intravenous doses were 2, 10, and 26 mg/kg. Pericardial procainamide prolonged right atrial effective refractory period from baseline by 22% (P < 0.01) but only at the 3.5 mg/kg cumulative dose. This dose slowed interatrial conduction time by 14% (P < 0.05) and raised atrial fibrillation threshold by 70 mA (P < 0.05). Pericardial procainamide had minimal effect on ventricular electrophysiology. Similar results occurred with a single 2 mg/kg pericardial dose in a closed chest model. Intravenous 10 and 26 mg/kg cumulative doses prolonged atrial effective refractory period from baseline by 24% and 18% (P < 0.01), respectively. The 26 mg/kg cumulative intravenous dose slowed interatrial and atrial-ventricular conduction times by 27% and 17%, respectively (P < 0.05), raised atrial fibrillation threshold, and slowed ventricular conduction time by 29% (P < 0.05). Pericardial procainamide produced pericardial fluid concentrations ranging from 250 to 1,500 microg/mL, but plasma concentrations were <1 microg/mL. Intravenous procainamide doses produced pericardial fluid concentrations similar to plasma trough concentrations 0 to 12 microg/mL. CONCLUSION: The single 2 mg/kg and 3.5 mg/kg cumulative pericardial procainamide doses prolonged atrial refractoriness and raised atrial fibrillation threshold similar to the 26 mg/kg cumulative intravenous dose, but the duration of effect was similar between delivery methods. Pericardial procainamide did not affect global or endocardial ventricular electrophysiology nor was it associated with ventricular proarrhythmia.
No takes yet. Share an insight, caveat, or question.
Ujhelyi et al. (2002) reported an RCT. Pericardial procainamide vs. Intravenous procainamide was evaluated on Right atrial effective refractory period prolongation from baseline (p=<0.01). Pericardial procainamide prolonged right atrial effective refractory period by 22%, achieving similar atrial electrophysiologic effects as a /kg intravenous dose.
Synapse has enriched 10 related papers. Consider them for comparative context: